RU2016151761A - Очищенные композиции белков ivig и kh для модулирования лимфоцитов и лечения вируса гепатита b - Google Patents

Очищенные композиции белков ivig и kh для модулирования лимфоцитов и лечения вируса гепатита b Download PDF

Info

Publication number
RU2016151761A
RU2016151761A RU2016151761A RU2016151761A RU2016151761A RU 2016151761 A RU2016151761 A RU 2016151761A RU 2016151761 A RU2016151761 A RU 2016151761A RU 2016151761 A RU2016151761 A RU 2016151761A RU 2016151761 A RU2016151761 A RU 2016151761A
Authority
RU
Russia
Prior art keywords
seq
amino acid
acid sequence
protein
substantially pure
Prior art date
Application number
RU2016151761A
Other languages
English (en)
Russian (ru)
Other versions
RU2016151761A3 (enExample
Inventor
Кью ХОАНГ
Original Assignee
Рэар Энтибоди Энтиджен Сеплай, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54699755&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2016151761(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Рэар Энтибоди Энтиджен Сеплай, Инк. filed Critical Рэар Энтибоди Энтиджен Сеплай, Инк.
Publication of RU2016151761A publication Critical patent/RU2016151761A/ru
Publication of RU2016151761A3 publication Critical patent/RU2016151761A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2016151761A 2014-05-28 2015-05-28 Очищенные композиции белков ivig и kh для модулирования лимфоцитов и лечения вируса гепатита b RU2016151761A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462003664P 2014-05-28 2014-05-28
US62/003,664 2014-05-28
PCT/US2015/032807 WO2015184050A1 (en) 2014-05-28 2015-05-28 Purified compositions of ivig and kh proteins for modulating lymphocytes and treating hepatitis b virus

Publications (2)

Publication Number Publication Date
RU2016151761A true RU2016151761A (ru) 2018-07-03
RU2016151761A3 RU2016151761A3 (enExample) 2018-12-26

Family

ID=54699755

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016151761A RU2016151761A (ru) 2014-05-28 2015-05-28 Очищенные композиции белков ivig и kh для модулирования лимфоцитов и лечения вируса гепатита b

Country Status (10)

Country Link
EP (1) EP3148574B1 (enExample)
JP (1) JP2017525752A (enExample)
CN (1) CN107106664A (enExample)
AU (1) AU2015266997A1 (enExample)
BR (1) BR112016027818A2 (enExample)
CA (1) CA2949994A1 (enExample)
ES (1) ES2878043T3 (enExample)
MX (1) MX2016015574A (enExample)
RU (1) RU2016151761A (enExample)
WO (1) WO2015184050A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106664A (zh) 2014-05-28 2017-08-29 美国稀有抗体抗原供应公司 用于调节淋巴细胞和治疗乙型肝炎病毒的ivig蛋白和kh蛋白的纯化组合物
CN107921079A (zh) * 2015-04-02 2018-04-17 K·黄 由组分iii制造静脉注射免疫球蛋白的方法
US10583179B2 (en) * 2015-04-02 2020-03-10 Kieu Hoang Method of manufacturing and purifying prothrombin complex concentrate from Fraction III for intravenous injection and a method of curing and preventing Hemophilia A with inhibitors or Hemophilia B in patients infected with HIV-1 and HIV-2
CN118878610B (zh) * 2024-03-19 2025-09-02 北京达尔文细胞生物科技有限公司 一种蛋白聚合物及其生产工艺

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3825429C2 (de) * 1988-07-27 1994-02-10 Biotest Pharma Gmbh Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
GB0315248D0 (en) * 2003-06-30 2003-08-06 Hoffmann La Roche HCV regulated protein expression
TWI489994B (zh) * 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
CA2639003A1 (en) * 2008-08-20 2010-02-20 Canadian Blood Services Inhibition of fc.gamma.r-mediated phagocytosis with reduced immunoglobulin preparations
KR20130070576A (ko) * 2010-04-09 2013-06-27 노보자임스 바이오파마 디케이 에이/에스 알부민 유도체 및 변이체
MX2012013233A (es) * 2010-05-14 2013-05-20 Univ Colorado Regents Grupos que apuntan a receptor 2 de complemento (cr2) mejorados.
TW201335181A (zh) 2012-01-31 2013-09-01 Kieu Hoang ５５種新發現的蛋白質之序列及其應用
CN107106664A (zh) 2014-05-28 2017-08-29 美国稀有抗体抗原供应公司 用于调节淋巴细胞和治疗乙型肝炎病毒的ivig蛋白和kh蛋白的纯化组合物

Also Published As

Publication number Publication date
BR112016027818A2 (pt) 2017-10-24
JP2017525752A (ja) 2017-09-07
EP3148574A1 (en) 2017-04-05
EP3148574A4 (en) 2017-04-05
WO2015184050A1 (en) 2015-12-03
ES2878043T3 (es) 2021-11-18
CN107106664A (zh) 2017-08-29
RU2016151761A3 (enExample) 2018-12-26
CA2949994A1 (en) 2015-12-03
MX2016015574A (es) 2018-05-28
EP3148574B1 (en) 2021-04-14
AU2015266997A1 (en) 2016-12-08

Similar Documents

Publication Publication Date Title
RU2603347C2 (ru) Очистка белка с использованием бис-трис буфера
CA2796409A1 (en) Process for preparing an immunoglobulin composition
JP3313117B2 (ja) ウイルス粒子の効率の高い生産および単離
CN105358571B (zh) 方法
JP2013530950A5 (enExample)
RU2013128866A (ru) Иммуногенные пептиды для применения в профилактике и/или лечении инфекционных заболеваний, аутоиммунных заболеваний, иммунных ответов на аллогенные факторы, аллергических заболеваний, опухолей, отторжения трансплантата и иммунных ответов против вирусных векторов, используемых для генной терапии или генной вакцинации
JP2011524887A5 (enExample)
CN106279432B (zh) 一种vc-car分子及在清除hiv-1感染细胞中的应用
CN103554253A (zh) 一种静注人免疫球蛋白的制备方法
ES2878043T3 (es) Composiciones purificadas de proteínas IVIG y KH para la modulación de los linfocitos y el tratamiento del virus de la hepatitis B
EP4628095A1 (en) Fusion protein and granulated antigen comprising same
JP2017525752A5 (enExample)
DE19504211A1 (de) Entfernen von Viren durch Ultrafiltration aus Proteinlösungen
JP2016531558A (ja) 高密度粗製細胞培養回収物の清澄化のための方法
CN102816230A (zh) 人血白蛋白的制备方法
CN107847541A (zh) 克隆并进一步纯化以制备重组静脉注射免疫球蛋白的方法
Race et al. An experimental chemically inactivated HIV-1 vaccine induces antibodies that neutralize homologous and heterologous viruses
CN118459605A (zh) 一种泛B亚族β冠状病毒广谱纳米颗粒疫苗及其制备方法
RU2493872C1 (ru) Способ очистки вируса гриппа
CN110616188B (zh) 一种通用型car-t细胞及其制备方法和应用
SE447789B (sv) Forfarande for framstellning av forsommar-meningo-encephalitis-virus-vacciner och genom forfarandet framstellda vacciner
JP2023526738A (ja) タンパク質の単純化した高効率単離のための組成物および方法
RU2018132668A (ru) Способ получения вирусбезопасного раствора иммуноглобулина g человека для внутримышечного введения
Watson et al. A factor that can be used to regulate an in vitro primary immune response
CN102344484A (zh) 提取光合膜蛋白(光系统ⅰ)的方法

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20200218